1350643-72-9

Basic information

• Product Name: Duvelisib int
• Synonyms: Duvelisib int;(S)-3-(1-aminoethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one;3-[(1S)-1-aminoethyl]-8-chloro-2-phenyl-1,2-dihydroisoquinolin-1-one;3-[(1S)-1-aminoethyl]-8-chloro-2-phenyl-1(2H)-Isoquinolinone;1(2H)-Isoquinolinone, 3-[(1S)-1-aminoethyl]-8-chloro-2-phenyl-;Duvelisib int (IPi-145 int )
• CAS NO: 1350643-72-9
• Molecular Formula: C₁₇H₁₅ClN₂O
• Molecular Weight: 298.77
• EINECS: 1592732-453-0
• Mol File: 1350643-72-9.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 477.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.296±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 10.59±0.29(Predicted)
• CAS DataBase Reference: Duvelisib int(CAS DataBase Reference)
• NIST Chemistry Reference: Duvelisib int(1350643-72-9)
• EPA Substance Registry System: Duvelisib int(1350643-72-9)

Safety Data

• Hazardous Substances Data: 1350643-72-9(Hazardous Substances Data)

Usage

General Description

Duvelisib is an investigational drug that belongs to a class of chemicals known as phosphoinositide 3-kinase (PI3K) inhibitors. It is being studied for its potential in treating a variety of illnesses, including relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Duvelisib functions by inhibiting the activity of PI3K, a key enzyme involved in cell growth, survival, and metabolism. By targeting this enzyme, duvelisib may help to slow or stop the growth of cancer cells, leading to potential therapeutic benefits for patients with these conditions. Clinical trials are currently underway to evaluate the safety and efficacy of duvelisib in different patient populations.

Upstream product

• 1420625-96-2 (S)-tert-butyl 1-(8-chloro-1-oxo-1H-isochromen-3-yl)ethylcarbamate 
• 1420625-93-9 C₁₆H₂₀ClNO₅ 
• 118-91-2 ortho-chlorobenzoic acid 
• 1386861-47-7 tert-butyl (S)-(4-(3-chloro-2-(phenylcarbamoyl)phenyl)-3-oxobutane-2-yl)carbamate 
• 1386861-46-6 2-chloro-6-methyl-N-phenylbenzamide 
• 89894-44-0 2-chloro-6-methylbenzoyl chloride 
• 21327-86-6 2-chloro-6-methylbenzoic acid 
• 146553-06-2 tert-butyl {(S)-1-[methoxy(methyl)amino]-1-oxopropan-2-yl}carbamate 
• 62-53-3 aniline 

Downstream Products

• 1350643-73-0 8-chloro-2-phenyl-3-((1S)-1-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-ylamino)ethyl)isoquinolin-1(2H)-one 
• 1350643-65-0 (S)-3-(1-aminoethyl)-8-(1-methyl-1H-pyrazol-4-yl)-2-phenylisoquinolin-1(2H)-one 
• 1420830-49-4 (S)-8-chloro-3-(1-(2-chloro-3-nitropyridine-4-ylamino)ethyl)-2-phenylisoquinolin-1(2H)-one 
• 1420829-86-2 C₂₃H₁₇ClN₄OS 
• 1420829-90-8 C₂₆H₁₉N₇OS 
• 1420830-50-7 C₂₂H₁₇ClN₄O₃S 
• 1420830-51-8 C₂₂H₁₉ClN₄OS 
• 1420830-03-0 C₂₇H₂₁N₇OS 
• 1420829-04-4 C₂₆H₂₁N₇OS 
• 1420829-13-5 C₂₈H₁₉F₃N₆OS 
• 1420618-60-5 C₂₈H₂₃N₇O 
• 1420619-03-9 C₂₉H₂₃N₇O 
• 1420623-31-9 C₂₃H₁₈ClN₇O 
• 1425042-18-7 (S)-2-amino-4-((1-(8-(2-methoxypyridin-4-yl)-1-oxo-2-phenyl-1,2-dihydroisoquinolin-3-yl)ethyl)amino)pyrimidine-5-carbonitrile 

Relevant articles and documents

Deregulation of hepatic mek1/2–erk1/2 signaling module in iron overload conditions

The liver, through the production of iron hormone hepcidin, controls body iron levels. High liver iron levels and deregulated hepcidin expression are commonly observed in many liver diseases including highly prevalent genetic iron overload disorders. In spite of a number of breakthrough investigations into the signals that control hepcidin expression, little progress has been made towards investigations into intracellular signaling in the liver under excess of iron. This study examined hepatic signaling pathways underlying acquired and genetic iron overload conditions. Our data? demonstrate that hepatic iron overload associates with a decline in the activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (Erk) kinase (Mek1/2) pathway by selectively affecting the phosphorylation of Erk1/2. We propose that Mek1/2-Erk1/2 signaling is uncoupled from iron-Bmp-Smad-mediated hepcidin induction and that it may contribute to a number of liver pathologies in addition to toxic effects of iron. We believe that our findings will advance the understanding of cellular signaling events in the liver during iron overload of different etiologies.

SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE

The invention relates to the preparation and use of new aminopyrirnidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the

Pyrimido oxazine derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases

The present invention relates to pyrimido oxazine derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same as an effective component for preventing or treating PI3 kinase-related diseases. The pyrimido oxazine derivatives according to the present invention have excellent selective inhibitory effects on PI3 kinase, and thus may be beneficially used in preventing or treating PI3 kinase-related diseases such as the following: cancers including blood cancer, ovarian cancer, cervical cancer, breast cancer, large intestine cancer, liver cancer, stomach cancer, pancreatic cancer, colon cancer, periotoneal cancer, skin cancer, bladder cancer, prostate cancer, lung cancer, osteosarcoma, fibrous tumor, and brain tumor; autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, hyperthyroidism, myasthenia gravis, Crohnandprime;s disease, ankylosing spondylitis, psoriasis, pernicious anemia, and Sjogrenandprime;s syndrome; and respiratory diseases including chronic obstructive pulmonary disease (COPD), rhinitis, asthma, chronic bronchitis, chronic pulmonary inflammatory diseases, silicosis, pulmonary sarcoidosis, pleuritis, alveolitis, vasculitis, emphysema, pneumonia, and bronchiectasis.COPYRIGHT KIPO 2017